ArticleFrontiers in genetics2026
HMMR as a robust prognostic biomarker correlates with immune infiltration and cell cycle pathways in oral squamous cell carcinoma: a multi-cohort bioinformatics analysis based on TCGA and GEO databases.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oral squamous cell carcinoma (OSCC), a prevalent head and neck malignancy with complex molecular pathogenesis and poor prognosis, remains a critical clinical challenge. This study aimed to elucidate the role of hyaluronic acid mediated motility receptor (HMMR) in OSCC progression and evaluate its potential as a diagnostic and prognostic biomarker. Methods: Transcriptomic data was integrated from the TCGA OSCC cohort and two independent GEO cohorts (GSE37991, GSE41613). Differential expression analysis was performed using DESeq2. Common differentially expressed genes (DEGs) were identified via Venn diagram analysis, followed by functional enrichment analysis using the STRING database. Univariate and multivariate Cox regression analyses were conducted with the survival package to identify prognostic markers, and the predictive performance was evaluated by receiver operating characteristic (ROC) analysis. Immune infiltration analysis, pathway enrichment analysis, and protein-protein interaction (PPI) network analysis via GeneMANIA were further applied to explore biological functions. Results: A total of 2,477 upregulated and 2,214 downregulated differentially expressed genes (DEGs) were identified, with 245 common DEGs pinpointed across datasets. Cluster1 genes were significantly associated with OSCC pathogenesis in functional enrichment. CCNA1, HMMR, and RAG1 were identified as potential prognostic markers, with HMMR demonstrating the strongest predictive value (AUC = 0.919 in ROC analysis). HMMR was significantly overexpressed in OSCC tissues compared to normal controls (P < 0.001), and its high expression correlated with advanced T stage, N stage, pathological grade, shorter disease-specific survival, and disease-free survival. Multivariate analysis confirmed HMMR as an independent prognostic factor for overall survival. Immune infiltration analysis revealed that HMMR expression was positively correlated with 11 immune cell subsets, particularly Th2 cells (r = 0.465) and T helper cells (r = 0.356), suggesting a role in modulating the tumor immune microenvironment. Pathway enrichment linked HMMR to tumor proliferation, hypoxia response, DNA damage repair, and G2/M cell cycle checkpoints. The PPI network analysis identified HMMR-associated complexes involving cell cycle regulators (e.g., CDK1, CCNB1, AURKA), implicating roles in cell cycle regulation, DNA repair, and mitotic progression. Discussion: Collectively, this study establishes HMMR as a robust prognostic biomarker for OSCC, tightly associated with malignant progression, immune cell infiltration, and key oncogenic pathways. HMMR and its interacting network represent promising targets for OSCC precision medicine, offering new insights into diagnostic strategies and therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.